{"schema_version":"secwatch.filing_event.v1","accession":"0001396814-23-000008","form_type":"8-K","ticker":"PCRX","cik":"0001396814","company_name":"Pacira BioSciences, Inc.","filed_at":"2023-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.745968+00:00","generated_at":"2026-06-18T21:39:07.897710+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Pacira BioSciences reports record 2022 revenue of $667M; Q4 GAAP net loss widens to $10.1M","bullets":["Full-year 2022 revenue $666.8M (+23% YoY); GAAP net income $15.9M ($0.34 diluted EPS) vs $42.0M ($0.92) in 2021.","Q4 2022 revenue $172.0M (+8% YoY); GAAP net loss $10.1M ($0.22 loss per share) vs loss $5.1M in Q4 2021.","ZILRETTA net sales $105.5M full year; Q4 $28.0M (+121% YoY) driving growth. EXPAREL $536.9M (+6%) full year; Q4 $138.0M (-1%).","2023 guidance: EXPAREL net sales $570-580M, ZILRETTA $115-125M, non-GAAP gross margin 76-78%.","Submitted sNDA for EXPAREL sciatic/femoral nerve blocks; opened Houston Innovation & Training Center in Jan 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001396814-23-000008","json":"https://secwatch.observer/filing/0001396814-23-000008.json","markdown":"https://secwatch.observer/filing/0001396814-23-000008.md","text":"https://secwatch.observer/filing/0001396814-23-000008.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1396814/000139681423000008/0001396814-23-000008-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1396814/000139681423000008/pcrx-20230228.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T21:39:07.897710+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"34830816c5df821bc7fb578d0f3021bba2b654a7","claim":"Pacira BioSciences, Inc. reported the fourth quarter ended December 31, 2022 results: revenue $172.0 million, net income $10.1 million, EPS $0.22 per basic and diluted share.","evidence_excerpt":"Full-year revenues of $666.8 million and fourth quarter revenues of $172.0 million. • Full-year GAAP net income of $15.9 million or $0.35 per basic share and $0.34 per diluted share. • Fourth quarter GAAP net loss of $10.1 million or $0.22 per basic and diluted share.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1396814/000139681423000008/0001396814-23-000008-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2022"},{"label":"Revenue","value":"$172.0 million"},{"label":"Net income","value":"$10.1 million"},{"label":"EPS","value":"$0.22 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"59b541e92c2aa49a1144f98b38cab261074ccd77","claim":"Pacira BioSciences, Inc. reported the full-year ended December 31, 2022 results: revenue $666.8 million, net income $15.9 million, EPS $0.35 per basic share and $0.34 per diluted share.","evidence_excerpt":"Full-year revenues of $666.8 million and fourth quarter revenues of $172.0 million. • Full-year GAAP net income of $15.9 million or $0.35 per basic share and $0.34 per diluted share.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1396814/000139681423000008/0001396814-23-000008-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full-year ended December 31, 2022"},{"label":"Revenue","value":"$666.8 million"},{"label":"Net income","value":"$15.9 million"},{"label":"EPS","value":"$0.35 per basic share and $0.34 per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}